

## **REMARKS**

Favorable reconsideration is respectfully requested.

The claims are 1, 2, 4-14, 20, and 26-27.

Claims 1, 4, 7, 14 and 20 are currently amended. New claims 26 and 27 have been added. Claims 3, 15-19, 21-25 are cancelled.

Support for the "optionally substituted amino" amendment to claims 1, 4 and 7 can be found at page 13, line 29 to page 14, line 3 of the specification. Support for the "optionally substituted carbamoyl" amendment to claim 1 can be found at page 15, lines 8 to 12 of the specification. Support for the amendment to claim 1 which defines the substituents of the non-aromatic carbocyclic ring, non-aromatic heterocyclic ring, aryl, aryloxy, heteroaryl, and non-aromatic heterocyclic group, can be found at page 15, line 24 to page 16, line 17 of the specification.

Support for the amendment to claim 14 may be found at, for example, page 30, first full paragraph of the specification.

Support for the amendment to claim 20 may be found at, for example, page 53, line 8 to page 54, line 2 of the specification.

Support for new claim 26 may be found, for example, in Example 4, at page 54 of the specification.

Support for new claim 27 may be found, for example, in Example 5, at page 54 of the specification.

Accordingly, no new matter is added.

### **Claim Rejections – 35 U.S.C. §112, first paragraph**

Claims 21-22 are rejected under 35 U.S.C. §112, first paragraph as failing to comply with the enablement requirement. Claims 21 and 22 are cancelled by this amendment rendering this rejection moot.

**Claim Rejections – 35 U.S.C. §112, second paragraph**

Claims 1-25 are rejected under 35 U.S.C. §112, second paragraph as being indefinite.

Applicants respectfully traverse.

Claim 1 is currently amended to define the optionally substituted substituents thus fully addressing this rejection.

Claim 14 is currently amended to specify a pharmaceutically acceptable carrier which is supported in the specification at page 30. Claims 15 to 19 and 22 to 25 are cancelled.

Claim 20 is amended to recite pain as the condition to be treated. This is based on Example 3 of the specification.

In addition, the definition for W from claim 3 has been incorporated into claim 1 and claim 3 is presently cancelled.

The above amendments are fully responsive to the points set forth in the Official Action and each of the issues raised by the Examiner have been fully addressed.

No further issues remaining, allowance of this application is respectfully requested.

If the Examiner has any comments or proposals for expediting prosecution, please contact undersigned at the telephone number below.

Respectfully submitted,

Hiroyuki KAI

By: J. Mark Konieczny

J. Mark Konieczny  
Registration No. 47,715

*for*  
Matthew M. Jacob  
Registration No. 25,154  
Attorney for Applicants

MJ/JMK/aas  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
July 17, 2008